Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR5 | P32302 | 5/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2228895 | 0.86 | CXCR5 (0.53) | CXCR5HTTTSHRHPGDSMN1; SMN2 | |
| SCHEMBL12164009 | 0.85 | HPGD (0.46) | CXCR5HTTTSHRHPGDSMN1; SMN2 | |
| SCHEMBL6859420 | 0.80 | KDM4E (0.52) | CXCR5TSHRHPGDL3MBTL1KMT2A | |
| SCHEMBL28638059 | 0.80 | CXCR5 (0.47) | CXCR5HTTTSHRHPGDSMN1; SMN2 | |
| SCHEMBL20161944 | 0.79 | CXCR5 (0.47) | CXCR5HTTTSHRSMN1; SMN2L3MBTL1 | |
| SCHEMBL27556126 | 0.79 | CYP3A4 (0.46) | CXCR5HTTTSHRHPGDL3MBTL1 | |
| SCHEMBL13477779 | 0.78 | ALDH1A1 (0.58) | HTTHPGDSMN1; SMN2L3MBTL1KMT2A | |
| SCHEMBL4155532 | 0.78 | KMT2A (0.50) | HTTTSHRHPGDL3MBTL1KMT2A | |
| SCHEMBL458942 | 0.78 | HPGD (0.66) | HTTTSHRHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL7632582 | 0.77 | NAAA (0.59) | HTTTSHRHPGDSMN1; SMN2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735384-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130040931-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011090911-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040931-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APH1B | CXCR5 4427/4885HTT 2538/4885TSHR 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.